Financial Performance - Revenue for Q3 2022 was CNY 106,086,181.83, a decrease of 79.54% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 was CNY 31,976,384.64, down 83.83% year-on-year[4] - Basic earnings per share for Q3 2022 was CNY 0.16, a decline of 91.84% compared to the previous year[4] - Operating income for the first nine months of 2022 was CNY 563,363,651.68, down 56.84% year-on-year due to increased market competition[10] - The company's total revenue for the current period was CNY 563,363,651.68, a decrease of approximately 56.7% compared to CNY 1,305,360,240.59 in the same period last year[27] - The net profit for Q3 2022 was CNY 151,155,941.78, a decrease of 65.7% compared to CNY 440,682,536.29 in Q3 2021[28] - Operating profit for the quarter was CNY 169,888,387.28, a decline of 66.7% from CNY 510,138,452.87 in the same period last year[28] Assets and Liabilities - Total assets at the end of Q3 2022 reached CNY 4,798,187,821.59, an increase of 193.62% from the end of the previous year[4] - As of September 30, 2022, the total assets of Shandong Sanyuan Biotechnology Co., Ltd. amounted to CNY 4,798,187,821.59, a significant increase from CNY 1,634,157,434.85 at the beginning of the year[23] - The total liabilities of the company as of September 30, 2022, were CNY 189,942,474.74, down from CNY 588,828,870.18, a reduction of approximately 67.8%[25] Equity and Shareholder Information - The company reported a significant increase in total equity attributable to shareholders, which reached CNY 4,608,245,346.85, up 340.84% from the previous year[4] - The equity attributable to the owners of the parent company increased to CNY 4,608,245,346.85 from CNY 1,045,328,564.67, reflecting a growth of about 340.5%[25] - The total number of ordinary shareholders at the end of the reporting period was 21,514, with no preferred shareholders having restored voting rights[14] - The largest shareholder, Nie Zaijian, holds 45.94% of the shares, totaling 92,946,000 shares[14] - The company completed a capital increase from capital reserves, increasing the total share capital from 134,883,800 shares to 202,325,700 shares, with a distribution of 5 shares for every 10 shares held[19] Cash Flow - Cash flow from operating activities for the first nine months of 2022 was CNY 90,426,851.62, down 82.62% compared to the previous year[4] - The net cash flow from operating activities for the first nine months of 2022 was ¥90,426,851.62, a decrease of 82.62% compared to the same period last year, primarily due to intensified market competition and a decline in sales prices and volumes[12] - The net cash flow from investing activities for the first nine months of 2022 was -¥3,282,248,061.08, an increase of 892.61% year-on-year, mainly due to the purchase of large bank deposits during the reporting period[12] - The net cash flow from financing activities for the first nine months of 2022 was ¥3,417,536,634.32, an increase of 53,306.88% compared to the same period last year, primarily due to funds raised from a public offering[12] Research and Development - Research and development expenses for the first nine months of 2022 amounted to CNY 31,870,190.36, a decrease of 34.44% compared to the previous year[10] - Research and development expenses amounted to CNY 31,870,190.36, down 34.5% from CNY 48,614,684.08 in the previous year[28] Operational Changes - The company obtained AEO Advanced Certification on September 30, 2022, which enhances its credibility and operational efficiency in international trade[21] - The company has changed its external auditor to Dahua Certified Public Accountants for the 2022 fiscal year, indicating a strategic shift in its auditing approach[20] - The company has not disclosed any related party relationships among the top ten shareholders[15] - The company has not reported any new product developments or market expansion strategies during the reporting period[18] Inventory and Receivables - Accounts receivable decreased significantly to CNY 33,583,700.39 from CNY 141,359,628.59, indicating a reduction of approximately 76.3%[23] - Inventory levels decreased to CNY 73,203,380.23 from CNY 112,157,402.58, representing a decline of about 34.7%[24] Cash and Cash Equivalents - The company's cash and cash equivalents as of September 30, 2022, were CNY 514,413,874.36, slightly down from CNY 515,719,690.44 at the beginning of the year[23] - The company reported a total cash and cash equivalents balance of CNY 514,832,741.03 at the end of the quarter, compared to CNY 254,249,794.17 at the end of Q3 2021[31]

Financial Performance - The company's revenue for Q1 2022 was ¥272,598,107.02, representing a 3.46% increase compared to ¥263,493,075.06 in the same period last year[3] - Net profit attributable to shareholders decreased by 9.64% to ¥62,765,994.16 from ¥69,465,064.33 year-on-year[3] - Basic and diluted earnings per share fell by 26.09% to ¥0.51 from ¥0.69 in the same period last year[3] - Total operating revenue for Q1 2022 was CNY 272,598,107.02, an increase from CNY 263,493,075.06 in the previous period[20] - Net profit for Q1 2022 was CNY 62,765,994.16, down from CNY 69,465,064.33 in the previous period, indicating a decrease of approximately 9.7%[21] - Earnings per share for Q1 2022 were CNY 0.51, compared to CNY 0.69 in the previous period, showing a decline[22] Cash Flow - The net cash flow from operating activities dropped significantly by 84.24% to ¥20,443,976.73, down from ¥129,686,530.82 in the previous year[3] - The net cash flow from operating activities for Q1 2022 was ¥20,443,976.73, a decrease of 84.25% compared to ¥129,686,530.82 in Q1 2021[25] - Total cash inflow from financing activities was ¥3,573,401,313.01, while cash outflow was ¥22,336,495.47, resulting in a net cash flow of ¥3,551,064,817.54[26] - The net increase in cash and cash equivalents for the period was ¥9,191,788.52, compared to an increase of ¥83,423,153.69 in the previous year[26] - The total cash and cash equivalents at the end of the period stood at ¥267,134,010.23, up from ¥141,186,753.95 at the end of Q1 2021[26] - The company reported cash inflow from operating activities totaling ¥312,922,891.80, an increase from ¥290,470,739.70 in the same period last year[25] - Cash outflow for purchasing goods and services was ¥266,221,244.95, significantly higher than ¥139,392,617.05 in Q1 2021[25] - The company recorded cash inflow from investment activities of ¥477,900.00, while cash outflow was ¥3,563,181,945.45, leading to a net cash flow of -¥3,562,704,045.45[25] - The company received ¥3,567,762,730.40 from investment activities, indicating strong capital inflow during the quarter[26] Assets and Liabilities - Total assets increased by 213.32% to ¥5,120,094,004.66 compared to ¥1,634,157,434.85 at the end of the previous year[3] - Total liabilities for Q1 2022 were CNY 465,185,884.07, down from CNY 588,828,870.18 in the previous period[18] - The company's equity attributable to shareholders was CNY 4,654,908,120.59, significantly higher than CNY 1,045,328,564.67 in the previous period[18] - Deferred income tax liabilities increased to CNY 25,228,040.35 from CNY 23,025,951.67 in the previous period[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 21.906 million[11] - The largest shareholder, Nie Zaijian, holds 45.94% of shares, totaling 61,964,000 shares[11] Investment and Subsidiary Activities - The company raised a total of RMB 3,685,705,300 from the public offering of 33.721 million shares at RMB 109.3 per share[13] - The net amount raised after deducting issuance costs was RMB 3,546,644,640.40[13] - The company established a wholly-owned subsidiary, Sanyuan Biological Engineering Research (Tianjin) Co., Ltd., with an investment of RMB 5 million[14] Other Financial Metrics - Cash received from tax refunds increased by 47.42%, primarily due to an increase in VAT refunds during the reporting period[8] - The company experienced a 90.99% increase in cash paid for purchasing goods and services, attributed to rising raw material prices and a shift in payment methods[8] - Other payables increased by 44.69%, mainly due to an increase in customer deposits for yeast mud sales[9] - Research and development expenses for Q1 2022 were CNY 10,219,983.55, slightly down from CNY 11,579,638.16 in the previous period[21] Audit Status - The report for Q1 2022 was not audited, which may affect the reliability of the financial data presented[27]

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 15%[17]. - The company's operating revenue for the reporting period was approximately ¥457.28 million, a decrease of 41.89% compared to the same period last year[26]. - The net profit attributable to shareholders was approximately ¥119.18 million, down 50.93% year-on-year[26]. - The net cash flow from operating activities was approximately ¥32.36 million, reflecting a significant decline of 88.16% compared to the previous year[26]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2022, representing a year-over-year growth of 20%[111]. - The company reported a net profit for the first half of 2022 of CNY 119,527,796.34, a decrease of 50.7% compared to CNY 242,889,853.19 in the same period of 2021[184]. - The total revenue for the first half of 2022 was CNY 5,557,800,000, representing a year-on-year increase of 33.7%[194]. Profitability and Margins - The gross profit margin improved to 35%, up from 30% in the same period last year[17]. - The company achieved a gross margin of 18.33% for erythritol, down 22.37% year-on-year, with revenue decreasing by 47.36%[56]. - The overall gross profit margin decreased from 42.27% in 2020 to 21.30% in the first half of 2022, reflecting challenges in maintaining high profitability[89]. - The gross margin improved to 45%, up from 40% in the previous year, reflecting better cost management[110]. - The company reported a significant increase in retained earnings, contributing to a stronger equity position[193]. Research and Development - The company plans to invest RMB 100 million in R&D for new product development in the next fiscal year[17]. - Investment in R&D increased by 25% year-on-year, focusing on innovative biotechnology solutions[110]. - The company is focusing on R&D in synthetic biology and has established a wholly-owned subsidiary to enhance its technological capabilities[49]. - The company has set a target to increase its R&D investment to 10% of total revenue, emphasizing the importance of innovation in its growth strategy[117]. Market Expansion and Strategy - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 10% market share by 2025[17]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[110]. - The company plans to focus on market demand by vigorously developing new technologies and products, aiming to launch high-value-added products that meet market needs[90]. - A strategic acquisition of a local biotech firm is anticipated to enhance product offerings and accelerate growth[110]. Operational Efficiency - The conversion rate of raw materials to end products improved to 85% in the reporting period[15]. - The company has adopted a procurement model based on "production-driven ordering and price comparison," ensuring efficient supply chain management[34]. - The company has set a target to reduce operational costs by 15% over the next year through efficiency improvements[110]. - The company aims to improve its operational efficiency, targeting a reduction in production costs by 5% through process optimization[111]. Shareholder and Capital Management - No cash dividends or stock bonuses will be distributed for this fiscal year[5]. - The company has not reported any changes in fundraising projects during the reporting period[76]. - The company has a commitment to not transfer or delegate the management of shares held prior to the public offering for 12 months[109]. - The company will prioritize measures such as stock repurchase, shareholding increase by controlling shareholders, and management stock purchases to stabilize the stock price[112]. Risk Management - The company faces risks related to supply chain disruptions and has implemented measures to mitigate these risks[4]. - The company faced a risk of intensified market competition in the erythritol industry, which could lead to price declines and increased sales expenses[83]. - The company acknowledges the existence of internal and external risks that may affect future profits, despite measures to protect shareholder interests[115]. Compliance and Governance - The company adheres to the ISO14001 environmental management system standards, ensuring compliance with environmental protection laws and regulations[102]. - The management emphasized the importance of adhering to regulatory compliance and maintaining shareholder trust during the upcoming growth phase[111]. - The company will publicly disclose reasons for not implementing stabilization measures if conditions are met but not acted upon, and will apologize to investors[112]. Assets and Liabilities - The total assets at the end of the reporting period reached approximately ¥4.87 billion, an increase of 198.26% from the end of the previous year[26]. - The company's total liabilities decreased to CNY 297,710,441.18 from CNY 588,828,870.18, indicating a reduction of approximately 49.6%[174]. - The equity attributable to the parent company increased significantly to CNY 4,576,268,962.21 from CNY 1,045,328,564.67, marking an increase of around 338.5%[174].

证券代码：301206 证券简称：三元生物 公告编号：2024-006 山东三元生物科技股份有限公司 2024 年第一次临时股东大会通知公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）第四届董事会第十九 次会议决定于 2024 年 2 月 20 日（星期二）召开公司 2024 年第一次临时股东大 会，现将本次会议有关事项通知如下： 一、召开会议的基本情况 （一）股东大会届次：2024 年第一次临时股东大会 （二）股东大会的召集人：公司董事会。 （三）会议召开的合法、合规性：本次股东大会会议召开符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》的规定。 （四）会议召开的日期、时间： 1、现场会议召开时间：2024 年 2 月 20 日（星期二）15:00 2、网络投票时间：2024 年 2 月 20 日（星期二） （2）通过深圳证券交易所互联网系统投票的时间为 2024 年 2 月 20 日 9:15-15:00 （五）会议的召开方式：本次股东大会采用现场表决与网络投票相结合的方 式召开。 1 / 9 ...

中信建投证券股份有限公司 关于山东三元生物科技股份有限公司 使用部分暂时闲置自有资金进行现金管理 的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐机构"） 作为山东三元生物科技股份有限公司（以下简称"三元生物"或"公司"）首次 公开发行股票并在创业板上市之保荐机构，根据《深圳证券交易所创业板股票上 市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等相关规定，中信建投证券对三元生物拟使用部分暂时闲置自有资金进 行现金管理的事项进行了核查，核查的具体情况如下： 一、前次使用部分暂时闲置自有资金进行现金管理的基本情况 公司于 2023 年 2 月 8 日召开了第四届董事会第十四次会议和第四届监事会 第十一次会议，于 2023 年 2 月 24 日召开了 2023 年第一次临时股东大会，上述 会议审议通过了《关于使用部分暂时闲置自有资金进行现金管理的议案》。同意 公司在不影响正常生产、经营及确保资金安全的前提下，拟使用不超过 220,000 万元人民币暂时闲置自有资金进行现金管理。使用期限自公司 2023 年第一次临 时股东大会审议通过之日起 12 个月内有效 ...

证券代码：301206 证券简称：三元生物 公告编号：2024-003 本次会议以记名投票表决方式表决通过如下议案： （一）审议通过《关于继续使用部分暂时闲置募集资金（含超募资金）进 行现金管理的议案》； 山东三元生物科技股份有限公司 第四届监事会第十五次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、会议召开和出席情况 山东三元生物科技股份有限公司（以下简称"公司"）第四届监事会第十五 次会议于 2024 年 2 月 2 日下午 2:30 在公司会议室以现场方式召开。会议通知于 1 月 29 日以书面、电话方式通知到各位监事，本次会议应到监事 3 人，实到监 事 3 人，会议由监事会主席崔振乾主持，会议的召集、召开和表决程序符合《公 司法》和《公司章程》的有关规定，所作决议合法有效。 二、议案审议情况 为提高募集资金使用效率，合理利用闲置资金，增加资金收益，结合募集资 金使用情况，在不影响募集资金投资项目建设和保证募集资金安全使用的前提下， 公司拟继续使用不超过 240,000 万元人民币暂时闲置募集资金（含超募资金）进 行现金管理（拟购买安 ...

证券代码：301206 证券简称：三元生物 公告编号：2024-005 山东三元生物科技股份有限公司 关于继续使用部分暂时闲置自有资金进行现金管理的公 告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）于 2024 年 2 月 2 日 召开了第四届董事会第十九次会议、第四届监事会第十五次会议，会议审议通过 了《关于继续使用部分暂时闲置自有资金进行现金管理的议案》。为提高闲置自 有资金的使用效率，增加公司资金收益，同意公司在不影响正常生产、经营的前 提下，拟继续使用不超过 100,000 万元人民币暂时闲置自有资金进行现金管理。 使用期限自公司 2024 年第一次临时股东大会审议通过之日起 12 个月内有效，如 单笔交易的存续期超过了上述决议有效期，则有效期自动延续至单笔交易到期时 止，在上述投资额度和使用期限内资金可滚动使用。公司授权管理层在上述额度 范围及期限内行使投资决策、签署相关文件等事宜，具体事项由公司财务部负责 组织实施。现将具体情况公告如下： 一、前次使用部分暂时闲置自有资金进行现金管理的基本情况 公 ...

山东三元生物科技股份有限公司 第四届董事会第十九次会议决议公告 证券代码：301206 证券简称：三元生物 公告编号：2024-002 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、会议召开和出席情况 度和使用期限内资金可滚动使用。暂时闲置募集资金（含超募资金）在现金管理 到期后将及时归还至募集资金专户。公司授权管理层在上述额度范围及期限内行 使投资决策、签署相关文件等事宜，具体事项由公司财务部负责组织实施。 具体内容详见公司于2024年2月3日在巨潮资讯网（www.cninfo.com.cn）披 露的《关于继续使用部分暂时闲置募集资金（含超募资金）进行现金管理的公告》 （公告编号：2024-004）。 表决结果：9 票同意，0 票反对，0 票弃权。 回避表决情况：本议案不涉及回避表决情况。 本议案尚需提交股东大会审议。 山东三元生物科技股份有限公司（以下简称"公司"）第四届董事会第十九 次会议于 2024 年 2 月 2 日上午 9:30 在公司会议室以现场+视频方式召开。会议 通知于 1 月 29 日以书面、电话方式通知到各位董事，本次会议应到董事 9 ...

山东三元生物科技股份有限公司（以下简称"公司"）于 2024 年 2 月 2 日 召开了第四届董事会第十九次会议、第四届监事会第十五次会议，会议审议通过 了《关于继续使用部分暂时闲置募集资金（含超募资金）进行现金管理的议案》。 为提高募集资金使用效率，合理利用闲置资金，增加资金收益，结合募集资金使 用情况，同意公司在不影响募集资金投资项目建设和保证募集资金安全使用的前 提下，拟继续使用不超过 240,000 万元人民币暂时闲置募集资金（含超募资金） 进行现金管理。使用期限自公司 2024 年第一次临时股东大会会议审议通过之日 起 12 个月内有效，在上述投资额度和使用期限内资金可滚动使用。公司授权管 理层在上述额度范围及期限内行使投资决策、签署相关文件等事宜，具体事项由 公司财务部负责组织实施。现将具体情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会证监许可【2021】4073 号文核准，并经深圳证 券交易所同意,公司向社会公众公开发行人民币普通股（A 股）3,372.10 万股，每 股面值为人民币 1.00 元，发行价为人民币 109.3 元/股，共计募集资金人民币 368,570.53 万元 ...

中信建投证券股份有限公司 关于山东三元生物科技股份有限公司 使用部分暂时闲置募集资金（含超募资金） 进行现金管理的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐机构"） 作为山东三元生物科技股份有限公司（以下简称"三元生物"或"公司"）首次 公开发行股票并在创业板上市之保荐机构，根据《上市公司监管指引第 2 号—— 上市公司募集资金管理和使用的监管要求》《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等相关 规定，中信建投证券对三元生物拟使用部分暂时闲置募集资金（含超募资金）进 行现金管理的事项进行了核查，核查的具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会证监许可【2021】4073 号文核准，并经深圳证 券交易所同意，公司向社会公众公开发行人民币普通股（A 股）3,372.10 万股， 每股面值为人民币 1.00 元，发行价为人民币 109.3 元/股，共计募集资金人民币 368,570.53 万元，扣除发行费用（不含税）后，公司本次募集资金净额为人民币 354,664.46 万元。募集资金已于 2022 年 1 ...